Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:47:41.559Z.
Consensus retrieved: 2026-10-06T14:42:33.654Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:47:41.559Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2828d634106ca83d862f06563bd3207250bf68b7c28fdcde625e8fc73480fe95
Forward PE Ratio (N/A) = Dated Quote Price ($7.34) / Consensus Forward EPS ($-1.50)
FORWARD PE RATIO
N/A
Ocular Therapeutix, Inc.
Market Cap
$1.61B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | $1.61B | N/A |
| Septerna Inc (SEPN)vs › | $1.61B | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 15.63 |
| uniQure N.V. (QURE)vs › | $1.60B | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 32.27 |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 7.71 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | N/A |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | N/A |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.61 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.34, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.50 | $-1.57 – $-1.44 | 7 | n/m |
| 2027-12-31 | $-1.47 | $-1.74 – $-0.99 | 7 | n/m |
| 2028-12-31 | $-1.02 | $-1.84 – $-0.45 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
